Kumsal Bayazit appointed Chief Executive Officer of Elsevier

Elsevier, the information analytics business specializing in science and health, today announced Kumsal Bayazit has been appointed Chief Executive Officer effective February 15, 2019.

Bayazit has worked at RELX Group, Elsevier’s parent company, since 2004. She started her career at Legal and Risk & Business Analytics, where she held a number of senior strategy and operational roles. In 2012, she was appointed Chief Strategy Officer of RELX Group, as well as chair of the company’s Chief Technology Officers’ Forum, formed to foster a strategic acceleration into an increasingly data-driven business focused on analytics and decision tools. For the past three years, she has been the Regional President for Europe, Middle East and Africa at RELX Group’s exhibitions business. Prior to joining RELX Group, Bayazit worked at Bain & Company in the US, South Africa and Australia. She holds an MBA from Harvard Business School and is a graduate of the University of California at Berkeley.

Bayazit replaces Ron Mobed who, after seven years as Elsevier’s Chief Executive Officer, has decided to retire. Mobed joined Elsevier in 2011 and became Chief Executive in 2012. He will support his successor during the transition, providing counsel and advice until June. Youngsuk (YS) Chi will remain Chairman of Elsevier.

---

About RELX Group

RELX Group is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs about 30,000 people of whom almost half are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £32bn, €37bn, $42bn. www.relx.com(打開新的分頁／視窗)

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation(打開新的分頁／視窗), we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX(打開新的分頁／視窗), a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.